A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

CompletedOBSERVATIONAL

Enrollment

22,369

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

March 30, 2024

Study Completion Date

March 30, 2024

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

BGF

Budesonide/glycopyrrolate/formoterol fumarate

DRUG

MITT

Multiple-inhaler triple therapy

Trial Locations (1)

AstraZeneca, Wilmington